Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis.
Ruemmele
F M
FM
Paediatric Gastroenterology, Hepatology and Nutrition, Hôpital Necker-Enfants Malades, Paris, France. frank.ruemmele@nck.ap-hop-paris.fr
Prieur
A-M
AM
Talbotec
C
C
Goulet
O
O
Schmitz
J
J
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D003424:Crohn Disease / Q000209:etiology* / Q000473:pathology; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects* / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept